EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer

William J Phillips iD, Fred Saad, Jennifer Leigh, Alborz Jooya, Colleen Webber, Scott Morgan, Robert MacRae, Jean-Marc Bourque, Peter Tanuseputro, Michael Ong iD

The Oncologist · 2024

DOI: 10.1093/oncolo/oyae036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von William J Phillips und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Medical Oncology, University of Ottawa, ON, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Bone Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GUMOC Astellas Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Anti-osteoclast treatment with denosumab or zoledronate is known to effectively reduce the need for radiotherapy to bone and other skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC). In this study, we analyze primary versus secondary initiation of bone-targeting agents (BTAs) relative to first palliative bone radiotherapy in patients dying of mCRPC.

Methods

Provincial administrative databases from Ontario, Canada identified patients with prostate cancer (2007-2018, n = 98 646) who received continuous androgen deprivation therapy (n = 29 453), died of prostate cancer (2013-2018, n = 3864), and received life-prolonging therapy for mCRPC (n = 1850). Variables were collected looking back 3 years from death. Multivariable analysis explored the relationship between clinical variables and BTAs.

Results

Of the 58% (1066/1850) patients with mCRPC who received BTA, only 289 (25.4%) started BTA prior to first palliative bone radiotherapy as primary prevention. Eight hundred and forty-eight (74.6%) patients either never received BTA before death (n = 447) or started BTA only after first bone radiotherapy (n = 401). More patients received denosumab (n = 825, 77%) than zoledronic acid (n = 241, 23%). 51.2% (582/1137) of palliative bone radiotherapy was initiated in the last 12 months of life. Factors associated with the use of BTA included elevated alkaline phosphatase (OR = 1.0, P = .023), de novo metastases (OR = 1.4, P = .005), medical oncologist involvement (OR = 2.0, P = .007), diagnosis 2012-2017 versus 2007-2011 (OR = 0.75, P = .034), and academic center (OR = 0.061, P = .007).

Conclusion

A majority of patients with mCRPC never receive BTAs prior to first SRE, despite universal access and availability of these agents in Ontario. These results highlight an opportunity to improve outcomes by emphasizing early introduction of BTA in patients with mCRPC being started on systemic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantBone NeoplasmsHumansMaleAgedBone Density Conservation AgentsAged, 80 and overMiddle AgedDenosumabZoledronic AcidOntario

Stichwörter der Autor:innen

bone-targeted agentsdenosumabprostate cancerskeletal-related eventszoledronate

Substanzen

Bone Density Conservation AgentsDenosumabZoledronic Acid

Autor:innen und Institutionen

  • Department of Medicine, Division of Medical Oncology, University of Ottawa, ON, Canada.
  • Centre Hospitalier de l'Université de Montréal, QC, Canada.
  • Department of Radiology, Radiation Oncology and Medical Physics, University of Ottawa, ON, Canada.
  • Ottawa Hospital Research Institute, Clinical Epidemiology Program, ON, Canada.
  • Department of Radiation Oncology, Centre Hospitalier de l'Universite de Montreal, QC, Canada.
  • Bruyere Research Institute, ON, Canada.

ORCID-Profile: William J Phillips, Michael Ong

Förderung

  • GUMOC Astellas Research

Zitieren

APA

Phillips, W. J., Saad, F., Leigh, J., Jooya, A., Webber, C., Morgan, S., MacRae, R., Bourque, J. M., Tanuseputro, P., & Ong, M. (2024). Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyae036

Vancouver

Phillips WJ, Saad F, Leigh J, Jooya A, Webber C, Morgan S, et al. Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer. The Oncologist. 2024. doi:10.1093/oncolo/oyae036

BibTeX
@article{Phillips2024,
  author = {Phillips, William J and Saad, Fred and Leigh, Jennifer and Jooya, Alborz and Webber, Colleen and Morgan, Scott and MacRae, Robert and Bourque, Jean-Marc and Tanuseputro, Peter and Ong, Michael},
  title = {Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyae036}
}
Kostenlos starten →